Tularik, Inc. (USA)

Creating Drugs That Regulate Gene Expression. Tularik engages in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. Our most advanced drug candidate, which we recently in-licensed from Eli Lilly, is T64 (formerly known as lometrexol). The utility of cancer drugs like T64 has been proven by methotrexate, a drug used extensively in the treatment of several tumor types. We initiated phase I combination studies and phase II clinical trials of T64 in July 2000. In August 2000, Tularik initiated a phase I study in the United Kingdom for its oral anti-cytomegalovirus drug candidate T611, In July 2000, Tularik began a phase I/II efficacy study in patients with hepatocellular carcinoma for its anti-cancer compound T67, Also in July 2000, Tularik initiated phase II efficacy and phase I combination studies for its anti-cancer compound T64 (lometrexol), In May 2000, Tularik and Japan Tobacco announced a major drug discovery alliance dedicated to the discovery of novel therapeutics for the treatment of metabolic diseases.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Bio
- Technology

Therapeutic targets:

- Genetics

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: